Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review

B-cell prolymphocytic leukemia (B-PLL) is a rare lymphoid neoplasm accounting for approximately 1% of all cases of lymphocytic leukemia. In this disease, TP53 abnormalities are found in more than half of the cases and about 50% of patients have MYC abnormalities (rearrangement and/or increased copy number). Similar to chronic lymphocytic leukemia (CLL), shortened survival in B-PLL is associated with TP53 mutations. Due to the rarity of this disease, most therapeutic approaches have been executed according to CLL guidelines. Specifically, Bruton’s tyrosine kinase (BTK) inhibitors show significant efficacy in CLL patients with 17p deletion/ TP53 mutation. However, little is known about the treatment outcome of BTK inhibitors (BTKi) in B-PLL. Here, we report for the first time the efficacy of a nextgeneration BTKi, zanubrutinib, combined with rituximab and lenalidomide (ZR2), in a B-PLL patient with TP53 and MYC abnormalities.

A 52-year-old man visited our hospital in October 2020 with a 3-year history of high white blood cell (WBC) count and splenomegaly. Physical examination revealed multiple palpable lymphadenopathies (bilateral neck, bilateral supraclavicular, bilateral axillary, and bilateral inguinal regions) and massive splenomegaly (19 cm below left costal margin). Complete blood count showed an elevated WBC count of 31.4×109/L, hemoglobin concentration of 134 g/L and platelet count of 87×10⁹/L. Peripheral blood (PB) smear revealed 88% of prolymphocytes. Serum lactate dehydrogenase (313 U/L, normal <250 U/L) and β2-microgloubulin (5.42 mg/L, normal <2.8 mg/L) were elevated. The concentration of serum monoclonal immunoglobulin G (IgG) with λ light chain, detected by immunofixation electrophoresis, was 2.8 g/L. Abdominal ultrasound showed splenomegaly (24.6×8.2 cm, 19 cm below left costal margin). 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scan showed slightly increased FDG metabolism of lymph nodes in the neck, axilla, mediastinum, retroperitoneum, abdominal cavity, pelvic cavity, and groin (the largest diameter is 1.5 cm, SUV_max 4.3). It also demonstrated increased FDG metabolism of spleen (SUV_max 4.3). A bone marrow (BM) biopsy showed B-PLL representing 75% of the marrow cells. Flow cytometry showed these cells were positive for CD19, CD79a, FMC7, CD81, CD22, CD20, and restricted monoclonal λ light chain, together with weakly positive for CD23, CD25, CD38, CD200, surface immunoglobulin M (sIgM), and negative for CD5, CD10, CD43, CD71, CD123, CD103, CD11c, surface IgD (sIgD) and κ light chain. These cells were stained negative for cyclin D1. Immunoglobulin heavy chain (IGH) somatic hypermutation analysis showed mutated IGH variable region genes. Cytogenetics revealed t(8;14) and fluorescense in situ hybridization (FISH) showed MYC gene rearrangement without CCND1/IgH rearrangement which exclude the diagnosis of mantle cell lymphoma (MCL). Molecular studies showed mutations in both MYC and TP53 genes. Based on cell morphology, histopathology, immunohistochemistry, genetic analysis, and clinical features, the patient was diagnosed as B-PLL.

This patient was treated with ZR2 regimen (zanubrutinib, 160 mg twice daily on day 1-21; lenalidomide, 25 mg once daily on day 1-14; rituximab, 375 mg/m² on day 1) every 28 days. Following the initiation of ZR2 treatment, the patient experienced resolution of splenomegaly, with the WBC decreasing from 31.4×10⁹/L to 8.43×10⁹/L after one cycle treatment (Table 1). Minimal residual disease (MRD) negative complete remission (CR) (by PB flow cytometry and PET-CT scan) was achieved after four cycles of ZR2 treatment, with monoclonal IgG disappearance. The patient refused allogeneic hematopoietic stem cell transplantation (HSCT). After 6 cycles of ZR2 treatment, MRD negative CR was further verified by PET-CT and flow cytometric analysis of bone marrow aspirates. Subsequently, the patient received two cycles of ZR (zanubrutinib, 160 mg twice daily on day 1-21; rituximab, 375 mg/m² on day 1) as consolidation therapy. Thereafter, zanubrutinib and lenalidomide (zanubrutinib, 160 mg twice; lenalidomide, 25 mg once daily on day 1-14; administered every 28 days) were used as maintenance therapy. Moreover, the patient has been well and has remained in sustained MRD-negative CR for 12 months by now. The most hematological adverse events were common grade 1-2 neutrophil count decrease, which can be recovered in a few days, and no significant non-hematological adverse events such as nausea and fatigue were noted.

There are an estimated 120 new cases of B-PLL per year in the United States and prospective clinical trials are currently not available. There is neither clear expert consensus nor are there guidelines for the treatment of BPLL, and the treatment according to CLL are frequently recommended as upfront therapy. In patients with TP53 mutation and/or deletion, alemtuzumab was an effective therapeutic option for these patients, despite showing a short reaction time. In a small series of idelalisib plus rituximab in B-PLL, responses were seen in all five patients, which lasts more than 6 months at the time of the report.¹

Table 1.Treatment course.

Table 2.Ibrutinib treatment in patients with B-cell prolymphocytic leukemia.

BTKi is known to promote high response rates, leading to durable remissions in all genetic subsets of CLL patients including patients with TP53 abnormalities. As shown in Table 2, ibrutinib has shown efficacy in individual case reports and small case series studies in B-PLL patients.^2-12 Zanubrutinib is a new-generation, irreversible BTKi demonstrating high selectivity and low toxicities. Zanubrutinib has demonstrated single agent safety and efficacy in B-cell malignancies including CLL, lymphocytic lymphoma (LPL) and MCL in several clinical trials. Lenalidomide is an immunomodulatory drug which has direct anti-tumor activity and indirect effects by enhancing anti-tumor immune responses. Lenalidomide can downregulate the expression of MYC and its target genes. Chamuleau et al. conducted a prospective R2- CHOP study on newly diagnosed MYC rearrangementpositive DLBCL patients which was safe and achieved 67% complete metabolic response.¹³ Bühler et al. reported that in a study of relapsed/refractory CLL patients treated with lenalidomide, there was no statistically significant difference in OS between TP53-mutant and wild-type patients.¹⁴ Additionally, for CLL patients who have high risk factors including TP53 mutation, the application of lenalidomide maintenance therapy can bring significant clinical benefits.¹⁵

Lenalidomide can enhance antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellmediated phagocytosis (ADCP) of rituximab, showing rational combination strategy with rituximab. Several studies have shown efficacy and safety of the combination of BTKi (ibrutinib or zanubrutinib) with R2 (lenalidomide and rituximab) and with or without chemotherapy (ibrutinib+R2+CHOP, clinicaltrials gov. Identifier: NCT02077166; ibrutinib+R2, clinicaltrials gov. Identifier: NCT02460276; ZR2+CHOP, clinicaltrials gov. Identifiers: EHA2021 EP548), to treat DLBCL and MCL. In a phase II trial (clinicaltrials gov. Identifier: NCT04460248) previously untreated elderly patients with DLBCL will be treated with ZR2 regimen.

Taken together, lenalidomide showed anti-tumor potential for MYC rearrangement-positive DLBCL and TP53-mutant CLL, in addition, ibrutinib+R2 showed efficacy for MCL, which may have similar disease characteristics as B-PLL. This patient has both TP53 and MYC mutations along with MYC rearrangement, which predicted the poor outcome with short survival period by conventional chemoimmunotherapy. Therefore, we employed ZR2 as a first line therapy for this patient. As far as we know, this is the first case report to document a successful treatment outcome with ZR2 as upfront therapy for a B-PLL patient.

Although effective standard treatment strategies have not yet been established for patients with B-PLL, we here demonstrate that ZR2 regimen induces a deep and durable response in one B-PLL patient with TP53 and MYC mutations along with MYC rearrangement. Given the poor prognosis of B-PLL and lack of effective established treatment modalities, this case report could represent a promising indication of ZR2 for B-PLL treatment. Further investigations in large cohort will be needed to characterize the efficacy, safety, and tolerability of this combination treatment.

Footnotes

• Received October 26, 2021
• Accepted December 16, 2021

Correspondence

ZENGJUN LI - zengjunli@163.com

Disclosures: no conflicts of interest to disclose.

Contributions: LX and ZL designed the study, performed treatments, collected and analyzed data, and wrote the manuscript; QH, LX and HW collected data on clinical follow-up. All authors approved the final version of the manuscript.

Ethics approval and consent to participate: this study was approved by the Medical Ethical Committee of Shandong Cancer Hospital and Institute. All patients’ samples were obtained with informed consent in accordance with the Declaration of Helsinki.

Data sharing statement: the data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding

this investigation was supported by the grant ZR2021MH072 to LX from Shandong Provincial Natural Science Foundation, China.

Acknowledgements

we are grateful to Teru Hideshima and Kenneth Wen at the Dana-Farber Cancer Institute for expert assistance in the revision and editing of the manuscript.